

CERAMENT® G AND CERAMENT® V contributes to improved survival rates

BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period.

The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment.

The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12.5%, vs 55.1%, $p < 0.00001$].

"By including the antibiotic eluting CERAMENT G and CERAMENT V in surgical treatment, we have improved infection statistics and dramatically reduced the risk of major amputations and mortality. Our hospital now uses antibiotic eluting CERAMENT as the standard treatment for diabetic foot," said Professor Anand Pillai, orthopedic and trauma surgeon at Manchester University Hospital and principal investigator of the study.

For more information contact:

BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
07 January 2025 11:05:00 CET



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

[CERAMENT® G AND CERAMENT® V contributes to improved survival rates](#)